Among patients treated with coronavirus, Aspirin use was associated with a significantly lower likelihood of needing mechanical ventilation (intubation), ICU admission and lower in-hospital mortality.
This is according to an observational study published in the medical journal Anesthesia & Analgesia. The professors of the Therapeutic Clinic of the Medical School of the National and Kapodistrian University of Athens, Efstathios Kastritis and Thanos Dimopoulos (rector of EKPA), summarize the findings of this study.
Study for aspirin in the coronavirus
As they report, To date, no studies have evaluated whether aspirin use is associated with a reduced risk of intubation and mechanical ventilation., ICU admission and in-hospital mortality, although it is one of the drugs used by many patients, who will need treatment for COVID-19.
The researchers analyzed data from 412 hospitalized patients with COVID-19 (middle age 55 years and 59,2% men) from a database, which contains information on COVID-19 patients from four major US hospitals. From patients, the 314 (76,3%) they were not taking aspirin. From those who received aspirin, the 75,5% received it before hospitalization and 86,7% received it inside 24 hours after admission to the hospital. The average dose of aspirin was 81 mg and the median duration of treatment was six days.
Patients taking aspirin had a significantly higher history of hypertension, type 2 diabetes 2, coronary heart disease and kidney disease. The percentage of patients in each group who received azithromycin, creature from recovering, dexamethasone, therapeutic dose of heparin, hydroxychloroquine, remdesivir and tocilizumab did not differ. Aspirin use was associated with lower frequency of need for mechanical ventilation and ICU entry, but showed no association with mortality during hospitalization. also, there were no differences in major bleeding or clinically apparent thrombosis between aspirin users and aspirin-free patients.
Based on the potential effect of aspirin on mechanical ventilation avoidance in patients with COVID-19, these results may be clinically significant, as the professors of EKPA emphasize. COVID-19 is associated with hypercoagulability and micro thrombosis in the vascular network of the lungs. This complication is one of the most common and serious in COVID-19 and is clearly associated with increased mortality., ventilation disorders and distant complications. Aspirin has a known anti-platelet effect and may possibly reduce the risk of these serious complications., even in addition to heparin. Aspirin is cheap, widely available and has a well-described security profile. These features, in combination with the pilot data of the study, support further investigation into the role of low-dose aspirin as a potential adjunctive therapy in COVID-19.